'Unprecedented' switching success gives Alexion hope in backstopping sales of blockbuster Soliris

Alexion's Soliris notched impressive sales growth in the third quarter despite an aggressive switching campaign. (Alexion)

Alexion scored a major win in its campaign to switch patients off blockbuster Soliris to follow-up drug Ultomiris with a second FDA approval earlier this week. That nod should help Ultomiris continue to gobble up patients—and it’s already ahead of plan, execs said Wednesday.

The majority of patients previously taking Soliris for paroxysmal nocturnal hemoglobinuria (PNH)—51% as of this week— have now switched over to Ultomiris, putting the successor drug well on its way to reaching a 70% U.S. conversion rate in that indication by mid-2020.

And in the meantime, Soliris itself is turning in big growth numbers, thanks to its own expansion into new indications.

Free Amazon Webinar

Performing end to end real-world evidence generation in the cloud with traceability and transparency- a Sanofi journey

In this webinar you will hear about Sanofi’s journey and experience in building an industrialized big data & analytics platform in the cloud that handles billions of rows of RWD data with complete data traceability, security, and supports both traditional and advanced analytics for day to day evidence generation (RWE).

In a third-quarter earnings call Wednesday, Alexion R&D chief John Orloff said the drugmaker had made “unprecedented progress” in switching patients to the newer med and highlighted conversion rates in Germany and Japan that have outstripped that in the U.S.

In Germany, 45% of PNH patients on Soliris had switched to Ultomiris as of Monday—around three months ahead of the time Ultomiris took to hit the same milestone in the U.S. In Japan, where Ultomiris was approved in PNH in June, more than 15% of patients have already switched over.

With Ultomiris’ FDA approval to treat atypical hemolytic uremic syndrome (aHUS) earlier this week, Alexion continues to position the drug well to pick up the expected slack when Soliris starts facing biosimilar competitors after 2023.

RELATED: Alexion scores 2nd FDA nod for Soliris successor drug as switching campaign continues

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.